Reality Check For Real World Data: FDA’s Sentinel Network Enters “Production” Stage
This article was originally published in RPM Report
Executive Summary
FDA’s Sentinel drug safety surveillance network has completed an important transition, moving from “experimental” to “production stage” as a tool to help inform post-market safety decisions. Now the question is whether real-world data can be used in making efficacy decisions.